

Bruton tyrosine kinase inhibitors for multiple sclerosis

In the format provided by the authors and unedited

Supplementary Table 1 | Clinical trials of BTK inhibitors in patients with autoimmune and malignant conditions.

Therapeutic indication	Phase	Notable trials (ClinicalTrials.gov Identifier)	Status
<i>Evobrutinib</i>			
Rheumatoid arthritis	2	NCT03233230, NCT02784106	Complete
SLE	2	NCT02975336	Terminated
SLE	1	NCT02537028	Complete
<i>Tolebrutinib</i>			
Myasthenia gravis	3	NCT05132569	Terminated
<i>Fenebrutinib</i>			
SLE	2	NCT02908100	Complete
Urticaria	2	NCT03693625	Terminated
B cell lymphoma, chronic lymphocytic leukaemia	1	NCT01991184	Completed
<i>Remibrutinib</i>			
Chronic spontaneous urticaria	3	NCT05170724, NCT05048342, NCT05032157, NCT05030311	Ongoing
<i>Orelabrutinib</i>			
Immune thrombocytopenia	2	NCT05232149, NCT05020288	Planned
Immune thrombocytopenia	1–2	NCT05124028	Planned
Primary CNS lymphoma	2	NCT05209620 ^a , NCT04899427 ^b	Ongoing
Primary CNS lymphoma	1–2	NCT04961515 ^c , NCT04831658 ^d	Ongoing
Primary CNS lymphoma	1–2	NCT05021770 ^e	Planned
Primary CNS lymphoma	1	NCT05036577 ^f	Recruiting
Follicular lymphoma	2	NCT04989621 ^g	Ongoing
B cell lymphoma	3	NCT05097443 ^h	Ongoing
B cell lymphoma	2	NCT05014100 ⁱ	Planned
B cell lymphoma	1–2	NCT04304040 ^j , NCT04014205	Ongoing
Non-Hodgkin lymphoma	1–2	NCT05021770 ^e	Planned
Mantle cell lymphoma	3	NCT05051891 ^h	Planned
Mantle cell lymphoma	2	NCT05076097 ^k	Ongoing
SLE	1–2	NCT04305197	Ongoing

Trials were identified on clinicaltrials.gov up to January 2022 (excluding trials in healthy volunteers and pharmacokinetic trials in patients with hepatic or renal impairment). BTK, Bruton tyrosine kinase; CNS, central nervous system; SLE, systemic lupus erythematosus. ^aCombination therapy with pemetrexed. ^bCombination therapy with sintilimab and tislelizumab. ^cCombination therapy with sintilimab. ^dCombination therapy with PD-1 monoclonal antibody and fotemustine. ^eCombination therapy with thiotepa. ^fCombination therapy with rituximab, methotrexate, and dexamethasone. ^gCombination therapy with rituximab. ^hCombination therapy with rituximab and combination chemotherapy. ⁱCombination therapy with lenalidomide. ^jCombination therapy with recombinant humanized monoclonal antibody MIL62. ^kCombination therapy with lenalidomide and rituximab.